@ikccorg.bsky.social๐ This World Mental Health Day, we recognise the emotional impact of kidney cancer on patients, carers and loved ones.
Mental health matters at every stage of the journey. Seeking support is important, and no one should have to face these challenges alone.
@kidneycan.bsky.socialClinical trials may be available at many different points in the #KidneyCancer treatment journey. Exploring whatโs available can give you more information to discuss with your healthcare team.
@ikccorg.bsky.social๐ Why are we part of the Global Patient Survey on #kidneycancer?
Because when local efforts are combined with a global approach, we can have the greatest impact on improving health equity and patient outcomes for people affected by kidney cancer: buff.ly/Mkj0pxs
@oncoalert.bsky.socialAfter IO, the road in #RCC gets murky ๐ซ๏ธ
So our good friends the UROMIGOS (Dr. Brian Rini & Dr. Tom Powles) asked global experts to score each option, from 0 (avoid) to 3 (SOC).
Where's the consensus, and where's the split? ๐ฅ
Dr. Laurence Albiges walks us through it ๐
@kidneycan.bsky.socialCould #KidneyCancer run in your family?
Join us October 28 for our FREE Town Hall, Genetics and Kidney Cancer: From Family Risk to the Future of Patient Care.
Register: https://kidneycan.org/genetics-kidney-cancer-family-risk
@ikccorg.bsky.social๐ The 5th Global Patient Survey on Kidney Cancer
This year marks an important milestone: 10 years of collecting data on the experiences of people living with kidney cancer. ๐
Your experience matters. Add your voice and take part in the survey today: buff.ly/7mCplWI
@kidneycan.bsky.socialThis is the 5th IKCC Global Patient Survey, marking 10 years of collecting data specific to the experiences of people living with #KidneyCancer. This milestone makes it possible to track trends and demonstrate changes over time.
@ikccorg.bsky.socialBy addressing both awareness and the emotional impact of kidney cancer, the project aims to help patients and families feel better informed, supported and less alone.
#IKCCGrants #KidneyCancer #KidneyCancerAwareness #CancerSupport
@kidneycan.bsky.socialPowered by AI and built specifically for people with #KidneyCancer, the Clinical Trial Navigator helps make complex clinical trial information easier to search and understand.
@cancerpatientseu.bsky.socialAt @uroweb.org event โClosing the Gap: Tackling Inequalities in #KidneyCancer Prevention and Careโ, CPE CEO Antonella Cardone shared CPEโs recommendations for a stronger, more sustainable European cancer policy.
๐ Read the EAU white paper: d56bochluxqnz.cloudfront.net/media/EAU_Wh...
@kidneycan.bsky.socialNeed some direction when it comes to clinical trials?
Meet the KidneyCAN Clinical Trial Navigatorโa free, AI-powered tool designed specifically to help people with #KidneyCancer explore trials that may be relevant to them.
@actionkidneycancer.bsky.socialThank you to the Specialist Kidney Cancer Centre at the @NHS Royal Free Hospital team for raising awareness of #kidneycancer today.
People attending the information stall were engaged and keen to talk to the team about early signs and symptoms of kidney cancer to look out for.
#StrongerTogether
@estroradiotherapy.bsky.social๐ Yesterday at the European Parliament, Prof Piet Ost represented ESTRO for the launch of the EAU #KidneyCancer White Paper.
Multidisciplinary care saves lives when interventions like #SABR and #SBRT are accessible without disparity.
Thanks to our host MEPs and EAU! ๐
#radonc #Urology @uroweb.org
@ikccorg.bsky.social๐ Why participate in the Global Patient Survey on #kidneycancer?
The information gathered helps create education, support and advocacy programs that respond to the needs of people affected by kidney cancer. ๐
Take part: buff.ly/7mCplWI
@kidneycan.bsky.socialWhy participate in the Global Patient Survey on #KidneyCancer? The information gathered helps create education, support and advocacy programs that respond to the needs of people affected by kidney cancer.
Take the survey: https://bit.ly/IKCC_Kidney_Cancer_Global_Survey
@mskcancercenter.bsky.socialThe FDA has approved the drug belzutifan in combination with lenvatinib for patients with a type of #kidneycancer called clear cell renal cell carcinoma (ccRCC).
The approval was based on a clinical trial led by Dr. Robert Motzer, a genitourinary medical oncologist at MSK. https://bit.ly/4hiaiJO
@debmaskens.bsky.socialCommend this initiative to describe patient-relevant deterioration of #Qol during (and long after) adjuvant tx. See this often in #rcc #kidneycancer
Were patient co-authors involved? Those with lived experience?
#ppi #patientengagement
#cansky
@ikccorg.bsky.social๐
1 October 2026
๐ 12:00โ13:15
๐ European Parliament, Brussels
Hosted by MEP Tilly Metz and MEP Romana Jerkovic.
#KidneyCancer #EUHealth #CancerPolicy #EUCancerPlan #EuropeanParliament
@actionkidneycancer.bsky.socialPlease help #kidneycancer patients, the IKCC patient survey is now open.
Take 15minutes to complete the survey, your experiences will help shape kidney cancer care for the next decade.
For more info and complete the survey please follow the link:
actionkidneycancer.org/get-involved...
@dengyuemedicine.bsky.socialKidney cancer progressed after immunotherapy? ๐งฌ
FDA approved belzutifan (Weliregยฎ) + lenvatinib (Lenvimaยฎ) on Sept 28 for advanced clear cell RCC after PD-1/PD-L1 therapy: the first HIF-2ฮฑ inhibitor + VEGFR-TKI combo for these patients.